Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 399

Results For "SSI"

5598 News Found

Wacker to build biotechnology center in Munich
Biotech | June 28, 2022

Wacker to build biotechnology center in Munich

The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements


Lynparza gets positive opinion from EU CHMP as adjuvant treatment for germline BRCA-mutated early breast cancer
Drug Approval | June 28, 2022

Lynparza gets positive opinion from EU CHMP as adjuvant treatment for germline BRCA-mutated early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival in patients


50%+ patients delay cataract surgeries in India: Survey
Public Health | June 28, 2022

50%+ patients delay cataract surgeries in India: Survey

73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries


PHARMAP 2022 concludes with productive networking of pharma leaders
News | June 28, 2022

PHARMAP 2022 concludes with productive networking of pharma leaders

The Congress was held on June, 20-21, 2022 in Berlin, Germany


Pharma industry warming up towards adoption of digital technologies
Digitisation | June 27, 2022

Pharma industry warming up towards adoption of digital technologies

By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities


Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease
Drug Approval | June 27, 2022

Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease

The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects


Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against omicron
News | June 27, 2022

Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against omicron

Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine


Mandaviya chairs high level meeting to review COVID-19 status
Policy | June 24, 2022

Mandaviya chairs high level meeting to review COVID-19 status

The Minister directed officials to continue to focus on surveillance and on Whole Genome Sequencing to scan for any possible mutation and also directed for monitoring hospitalizations due to COVID-19 and SARI/ILI cases


Novartis commits US$ 250 million to the fight against NTDs and malaria
Public Health | June 24, 2022

Novartis commits US$ 250 million to the fight against NTDs and malaria

This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.


Novartis receives EC approval for Tabrecta for the treatment of non-small cell lung cancer
Drug Approval | June 24, 2022

Novartis receives EC approval for Tabrecta for the treatment of non-small cell lung cancer

Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally